Growing evidence supports involvement of low-affinity/high-capacity organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) in regulating clearance of monoamines. Currently decynium-22 (D22) is the best pharmacological tool to study these transporters, however it does not readily discriminate among them, underscoring a need to develop compounds with greater selectivity for each of these transporters. We developed seven D22 analogs, and previously reported that some have lower affinity for α1-adrenoceptors than D22 and showed antidepressant-like activity in mice. Here, we extend these findings to determine the affinity of these analogs for OCT2, OCT3 and PMAT, as well as serotonin, norepinephrine and dopamine transporters (SERT, NET and DAT) using a combination of uptake competition with [ Like D22, all analogs showed greater binding affinities for OCT3 than OCT2 and PMAT. However, unlike D22, some analogs also showed modest affinity for SERT and DAT. Dual OCT3/SERT and/or OCT3/DAT actions of certain analogs may help explain their ability to produce antidepressant-like effects in mice and help account for our previous findings that D22 lacks antidepressant-like effects unless SERT function is either genetically or pharmacologically compromised. Though these analogs are not superior than D22 in discriminating among OCTs/PMAT, our findings point to development of compounds with combined ability to inhibit both low-affinity/high-capacity transporters, such as OCT3, and high-affinity/low-capacity transporters, such as SERT, as therapeutics with potentially improved efficacy for treatment of psychiatric disorders.
OCTs and PMAT and is currently the best available pharmacological tool to probe their contribution to monoamine uptake. For example, D22 inhibits substrate uptake in rat CNS neurons (Hill et al., 2011) ; blocks serotonin uptake in SERT knockout mouse brain synaptosomes (Hagan et al., 2011) ; increases hypothalamic extracellular serotonin (5-HT) in rats (Feng et al., 2005 (Feng et al., , 2010 ; potentiates the antidepressant-like effect of a selective serotonin reuptake inhibitor (SSRI) in wildtype mice (Horton et al., 2013) ; and produces antidepressant-like effects in a rat model of depression (Marcinkiewcz and Devine, 2015) . Additionally, D22 produces antidepressant-like effects in heterozygous and homozygous SERT knockout mice where OCT3 expression is increased, an effect that is absent in wildtype counterparts (Baganz et al., 2008) ; and the OCT3 inhibitor corticosterone, potentiates fenfluramine-induced increases in hypothalamic extracellular serotonin levels in rats (Feng et al., 2009) . Thus, while the latter studies point to OCT3 as perhaps the primary low-affinity/high-capacity transporter mediating these effects of D22, selective pharmacological tools are sorely needed to untangle specific contributions of OCTs and PMAT.
To this end, we evaluated novel D22 analogs for selectivity to inhibit substrate transport in OCT2, OCT3, and PMAT heterologous cell expression systems, and in mouse hippocampal and striatal preparations. Chosen analogs were based upon availability of essential chemical precursors (e.g. 6-substituted-2-methyl quinolines). Five analogs contained varying isocyanine ring substituents (halogen and methoxy groups), two were based upon the structurally related cyanine heterocyclic ring system (Table 1) . Initial characterization showed that the analogs were significantly less potent inhibitors at alpha-1 adrenergic receptors (compounds 2, 5, 6 & 7), giving these analogs potential for lesser in vivo off-target effects than D22 (Krause-Heuer et al., 2017) . Moreover, some analogs were less potent inhibitors of spontaneous locomotor activity (compounds 6 & 7) , and independently, showed antidepressant-like activity (i.e. reduced time spent immobile) in the mouse tail suspension test (compounds 5 & 6) (Krause-Heuer et al., 2017) . This independent antidepressant-like effect is unique given our previous studies showed D22 to produce antidepressant-like effects in wildtype mice only when given with a sub-effective dose of a selective serotonin reuptake inhibitor (SSRI) (Horton et al., 2013) , or when given to mice with genetically reduced SERT expression (Baganz et al., 2008) . However, it remains unclear if D22, or its analogs, have any activity at the high-affinity/low-capacity transporters DAT, NET, and SERT. Likewise, which of the low-affinity/high-capacity transporter(s) mediate the antidepressant-like effects of D22, and certain analogs, remains unclear.
We found that these analogs are not superior to D22 in discriminating among OCTs/PMAT. However, importantly, we found that analogs with stand-alone antidepressant-like activity (previously reported (Krause-Heuer et al., 2017) ) support the development of compounds with combined ability to inhibit both low-affinity/high-capacity transporters, such as OCT3, and high-affinity/low-capacity transporters, such as SERT, as therapeutics with potentially improved efficacy for treatment of psychiatric disorders.
Materials and methods

2.1 Chemicals and supplies
All chemicals were purchased from Sigma Aldrich (St. Louis, MO), unless otherwise noted. (Krause-Heuer et al., 2017) and provided by the Australian Nuclear Science and Technology Organisation (ANSTO). Glass microfiber filter mats used in radioligand experiments were supplied by Brandel Inc. (Gaithersburg, MD).
Animal use and brain tissue preparation
Male, wild type C57BL/6 mice were cared for and used through IACUC approved university protocols in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice of ages 4-12 months were rapidly killed via cervical dislocation and decapitation. Whole hippocampi or striata were dissected, on ice, from the left and right hemispheres, and quickly frozen in a 1.5 ml microfuge tube on dry ice. Brain tissue from two mice per experiment were combined and stored at −80°C until further use. To prepare tissue homogenate, dissected brain regions were thawed then homogenized twice for 10 s while kept on ice, using a Polytron homogenizer instrument (PT 3100 Model with generator PT-DA 3005/2EC), at 25,000 rpm (shear rate 4333 s -1 ). In between homogenizations, the tissue suspension was centrifuged at 25,000 × g for 10 min at 4°C in a Beckman Coulter floor centrifuge (Avanti J-E series, rotor JA 25.5). The final tissue pellet was suspended in~5 ml of appropriate uptake buffer containing protease inhibitor (Roche Diagnostics complete cocktail tablets, Indianapolis, IN) and homogenized with the Polytron instrument. Tissue homogenate solution was kept on ice until used in radioligand assays. A 50 µl aliquot of tissue homogenate was reserved to determine protein concentration using the BCA protein assay kit (Pierce Thermo Scientific). The average protein concentration of tissue homogenate used in binding assays ranged from 0.6 to 0.8 mg protein/100 µl.
Cell culture
Human embryonic kidney (HEK) cells that stably express human organic cation transporter 2 or 3 (hOCT2-HEK and hOCT3-HEK) were kindly provided by Dr. Dirk Grundemann (University of Cologne, Germany). The HEK cell line expressing human plasma membrane monoamine transporter (hPMAT-HEK) was generously provided by Dr. Joanne Wang (University of Washington, USA). Cells were maintained at 37°C/5% CO 2 in DMEM high glucose media (Gibco™) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Selection of expression vectors were maintained by the addition of 150 µg/ml of G418 (hOCT2-& hOCT3-HEK cells) or hygromycin B (hPMAT-cells) to the growth media. Cells were passaged up to 20 times or less and used for experimentation at approximately 80-90% growth confluency. 60 min at room temperature, respectively. The 8 final concentrations of unlabeled, competing ligands ranged from 0 to 10 mM. Non-specific binding was determined in the presence of 10 μM GBR12935 (DAT, striatum); 10 μM desipramine (NET, hippocampus); or 10 μM citalopram (SERT, hippocampus) as the final experiment concentrations.
At the end of the incubation period, binding was terminated with four rapid washes with ice-cold binding buffer via vacuum filtration onto a glass fiber, 48-well mat to trap transporter bound radioligand.
Each sample filter was transferred to individual scintillation vials with 4 ml of scintillation fluid. Radioactive counts were measured as described for uptake assays. previously described (Mayer et al., 2017) bility of D22 and its analogs, stock solutions of all drugs were prepared in 100% DMSO, with final reaction solutions containing 1% of DMSO. The uptake reaction was measured for 10 min at room temperature. Total uptake was measured in triplicate; one representative well for each concentration of competing ligand contained a high concentration (10 or 100 μM) of an inhibitor to determine non-specific uptake. Specific uptake was taken as the subtraction of non-specific from total uptake measurements. To terminate the uptake assay, the radioactive solution was gently aspirated. The cells were quickly washed, three times, with ice-cold phosphate buffered saline, then lysed in 250 µl 1% sodium dodecyl sulfate (SDS) to release transported [ 
Statistical analysis
Results from radioligand assays were analyzed using GraphPad Prism 7 software. Specific uptake or binding was taken as the averaged non-specific measurements subtracted from the total measurements at each concentration. The dependent variable, the specific uptake or binding measured, is reported as a percent of the control (zero concentration, in the absence of competing ligand) as a function of competing ligand concentrations plotted on a log-scale. Percent of control values are plotted as the mean of at least three independent experiments performed in duplicate or triplicate ± S.E.M. Human transporter uptake inhibition and mouse binding displacement data were fitted by non-linear regression analysis to determine the drug concentration to inhibit half the uptake/binding response (IC 50 ). A least-squares fitting method was applied for a one-site fit, logIC50 model using the equation: Y = Bottom + (Top-Bottom)/(1 +10^(X-LogIC 50 )). The best-fit IC 50 values were used to compare drug affinities among transporter subtypes. An extra sum-of-squares F test was applied to compare the fit of nested models, the null-hypothesis model of a common IC 50 between two compounds/transporters or the alternative hypothesis model of two different IC 50 values between comparisons. A p-value ≤ 0.05 determined whether to reject the null hypothesis that IC 50 values between data sets were the same and conclude the alternative hypothesis model as a better fit (i.e. the IC 50 values significantly differed). IC 50 values are reported with their 95% confidence interval to provide information about the precision of each estimation.
Results
Evaluations of D22 analogs at high-affinity/low-capacity transporters in mouse brain tissue
While literature reports have shown D22 to be a potent inhibitor of the low-affinity/high-capacity transporter family, its action at the highaffinity monoamine transporters, DAT, NET and SERT, remains questionable. It is also unknown if the novel analogs have activity at these transporters. It was therefore crucial to determine if behavioral effects of D22 and its analogs in mice could be attributed to their actions at these high-affinity monoamine transporters. Chemical structures for all compounds tested are provided in Table 1 . The D22 analogs include two isocyanine analogs, compounds 1 and 2 (Buettner, 1967) , and five pseudoisocyanines, compounds 3-7 (Table 1) . While 3 and 7 have been previously made (Russ et al., 1993a) , compounds 4, 5, and 6 are completely novel analogs; the full chemical characterization of all seven analogs has been recently published (Krause-Heuer et al., 2017) . To align with our use of mice in our published in vivo study (Krause-Heuer et al., 2017) , we assessed the selectivity of D22 and novel analogs to inhibit high-affinity/low-capacity transporters by measuring displacement of DAT, NET, and SERT specific, high-affinity radioligands. An appropriate transporter substrate and inhibitor was also included in the binding assessment. For ease of comparison, the concentration-response curve for a reference substrate and inhibitor, along with the parent D22, are repeated in the subfigure for each D22 analog in Figs. 1-3 . A complete summary of IC 50 values and statistical comparisons for all compounds tested in DAT, NET and SERT binding is provided in Table 2. greatest affinity as seen by its estimated IC 50 value in the low nanomolar range (Fig. 2 , Table 2 ). We found the known NET substrate, dopamine, to have an IC 50 value near 13 µM ( Table 2) . This is consistent with the long-standing establishment of dopamine as a favored substrate for NET when compared to DAT (Giros, et al., 1996; Gu et al., 1994; Moron, et al., 2002) . The parent D22 compound bound weakly to NET and was significantly less potent than dopamine (P = 0.0006). Some of the analogs, specifically compounds 2-5, were sub-potent inhibitors at NET, as demonstrated by similar binding profiles to dopamine's at displacing [ Table 2 ). On the other were tested for their ability to displace the high-affinity NET blocker [ 3 H]nisoxetine in 120 min binding assays performed on ice. Concentration-response curves obtained for unlabeled reference compounds are repeated in gray for each subfigure and include NET substrate dopamine (gray, closed squares), inhibitor desipramine (gray, closed circle), and decynium-22 (D22, gray, open square). The IC 50 determinations obtained from non-linear regression curve fits can be found in Table 2 . (Table 2 ). In summary, the apparent rank order for displacement binding at the mNET is as follows: desipramine > > > dopamine = analogs 2, 3, 4, 5 > analog 1, 6, 7 = D22.
In a similar fashion, binding of D22 analogs to SERT was evaluated through displacement of the high-affinity ligand [ (P = 0.27) to that of serotonin's binding displacement at SERT (Fig. 3 , Table 2 ). Several analogs including: compounds 1 (Figs. 3a) , 2 (Figs. 3b) , 3 (Figs. 3c), and 5 (Fig. 3e) shared a similar affinity for SERT as serotonin, with compounds 1, 2, and 5 also not being significantly different from D22. On the other hand, compounds 4 (Figs. 3d) , 6 (Figs. 3f), and 7 (Fig. 3g) , showed much greater affinity to displace binding at SERT in comparison to serotonin or D22 as demonstrated by their lower IC 50 values near 1 µM ( Table 2 ). The following rank order can best summarize the affinities for tested compounds to displace binding at SERT: citalopram > > > analog 4 ,6, 7 > 5-HT = D22, analog 1, 2, 3, 5. (Fig. 4) . Cocaine was, expectedly, the most potent of the inhibitors to block [ 3 H]MPP + uptake in all three high-affinity transporter cell lines. The IC 50 for cocaine to inhibit uptake at mDAT, mNET, and mSERT was determined to be 0.18, 1.2, and 0.5 µM, respectively 
IC 50 estimations determined from concentration response curves (Figs. 1-3 ) fit to a nonlinear regression. a P < 0.05, aa P < 0.01, and aaa P < 0.001 indicates significance of difference for the compound versus decynium 22 (D22) within each radioligand. b P < 0.05, bb P < 0.01, and bbb P < 0.001 denotes significant difference between the compound and reference transporter substrate, either dopamine (DAT and NET) or serotonin (SERT). Table 3 . Data represents an n of 3 independent experiments performed in duplicate fit to a non-linear regression analysis to determine estimated IC 50 values.
( Fig. 4A-C) . On the other hand, the known OCT3 inhibitor, corticosterone, was not a potent blocker of uptake via mDAT, mNET or mSERT, as seen by the rightward shifts in concentration-response analyses ( Fig. 4A-C at mNET, and 8 µM at mSERT (Table 3) . These data show modest activity of D22 at high-affinity/low-capacity transporters in the rank order of SERT > DAT > NET.
Evaluations of D22 analogs at human low-affinity/high-capacity transporter stable expressing cell lines
Finally, to increase translational relevance of our findings in mice to humans, we evaluated the ability of D22 and its analogs to inhibit [ comparison to both hOCT2 (P = 0.009) and hPMAT (P = 0.002) (Fig. 6A) . Inhibition potency of compound 1 did not differ between hOCT2 and hPMAT (P = 0.61). In contrast, the IC 50 for the isopropyl isocyanine, compound 2, was the same for all three transporters (Fig. 6B ).
All five pseudoisocyanines were potent uptake inhibitors at hOCT3 compared to either hOCT2 or hPMAT. The IC 50 values for [ 3 H]MPP + uptake inhibition by compounds 4, 5, 6, and 7 were the same between hOCT2 and hPMAT ( Fig. 6D-G) . In contrast, compound 3, was a more potent uptake inhibitor at hPMAT in comparison to hOCT2, but still significantly less effective than blockade at hOCT3 (Fig. 6C) . Apart from compound 2, all other D22 analogs were more potent inhibitors of uptake via hOCT3 versus either hOCT2 or hPMAT, as indicated by their significantly reduced IC 50 values (Table 4) . Within the hOCT2 cell line, comparisons between D22 and the analogs revealed significantly IC 50 estimations determined from concentration response curves (Fig. 4) fit to a nonlinear regression. a P < 0.05, aa P < 0.01, and aaa P < 0.001 indicates significance of difference for the drug versus decynium 22 within a cell line. b P < 0.05, bb P < 0.01, and bbb P < 0.001 indicates significance of difference for the compound compared to mDAT. ccc P < 0.001 indicates significant difference between mNET and mSERT. , or 100 µM for decynium-22, and 1 mM for corticosterone and are plotted on a log-scale. Uptake inhibition assays were performed at room temperature for 10 min. Data are fit to a non-linear regression analysis to determine IC 50 estimations (refer to Table 4 ). reduced potencies with compound 5 (P = 0.045 vs. D22) and compound 6 (P = 0.02 vs. D22), but similar potencies with the remaining compounds, 1-4 and 7 to inhibit uptake at hOCT2. Most analogs shared the same potency as D22 to inhibit uptake via hPMAT, except compounds 1 and 7 that were significantly less potent blockers (P = 0.002 and 0.02, respectively). The IC 50 values for all seven analogs were significantly greater than that of parent D22. Therefore, none of the compounds were more potent than the parent D22 to inhibit hOCT3-mediated uptake. Despite the analogs being less potent than the parent D22, their binding preference for hOCT3 is demonstrated in their compared potencies to the known OCT3 blocker, corticosterone. Here, we found both isocyanine compounds 1 and 2 were statistically less potent inhibitors of [ 3 H]MPP + uptake at hOCT3 compared to corticosterone. However, all the pseudoisocyanines, compounds 3-7, shared similar potencies as corticosterone, with the lowest IC 50 value being compound 5 at 0.4 μM (Table 4) .
Transporter binding preference for parent and D22 analogs
The observed transporter binding preference for parent and D22 analogs is summarized in Fig. 7 . Using the IC 50 values for each compound to inhibit [ 3 H]MPP + uptake, we generated a visual representation of the relative potency of corticosterone, parent D22, and the analogs at hOCT3 compared to hOCT2 or hPMAT (Fig. 7A) . Similarly, the IC 50 values for D22 or each analog to displace binding of radiolabeled inhibitors at mSERT was compared to mDAT or mNET (Fig. 7B) . All compounds shared a preference to inhibit hOCT3 mediated [ 3 H]MPP + uptake versus hOCT2 or hPMAT as indicated by their relative potency ratios falling below 1. In contrast, there was variation in the relative preference to bind mSERT. All the compounds favored binding to mSERT over binding to mNET (ratios less than 1). However, in comparison to mDAT, D22, compound 2, and compound 4 had ratio values above 1, suggesting a preference for mSERT versus mDAT.
Discussion
We previously characterized antidepressant-like effects of seven D22 analogs (Krause-Heuer et al., 2017 ). Here, we tested their binding specificity at high-affinity/low-capacity (SERT, DAT, NET) and lowaffinity/high-capacity (OCT2, OCT3, PMAT) transporters to understand the relationship between their affinity and ability to produce antidepressant-like behavioral effects in mice. All analogs bound with low affinity to mSERT, mDAT and mNET, determined by [ 1-3 ). D22 and a subset of the analogs (1, 2, 4, 6, 7) showed higher affinity for mDAT than the endogenous neurotransmitter dopamine (Table 2 , DAT column). Likewise, a smaller subset of the analogs (4, 6, 7) showed higher affinity for mSERT than the endogenous neurotransmitter 5-HT ( than hOCT2 or hPMAT (Fig. 6 , Table 4 ). Together with our previous behavioral characterization of these D22 analogs (Krause-Heuer et al., 2017) , and published findings (Horton et al., 2013) , our results suggest that multimodal inhibition at both low-and high-affinity transporter families may be a strategy for compound development with improved therapeutic efficacy for disorders like depression. Several investigations have elegantly demonstrated the contribution of corticosterone-or D22-sensitive transporters to monoamine clearance (Daws, 2009; Feng et al., 2009; Gasser et al., 2006 ; Hill et al., 2011; Shaskan and Snyder, 1970; Takeda et al., 2002; Yoshikawa et al., 2013; Zwart et al., 2001 ) . Mouse models are an essential preclinical resource to study the action of low-affinity transporters. Functional similarities have been observed between the uptake kinetics of substrates like dopamine, MPP + , and serotonin by human and mouse PMAT (Miura et al., 2017; Shirasaka et al., 2016) . On the other hand, hOCT3 and mOCT3 were found to share similar affinities for MPP + , but not serotonin (Massmann et al., 2014) . Others have found corticosterone to either have enhanced potency for hOCT3 (Gründemann et al., 2002) or equipotent blockade at hOCT3 and mOCT3 (Massmann et al., 2014) . Of the few studies that have evaluated species-specific transporter functions, observed differences can depend on the competing ligand, as well as experimental conditions (e.g. temperature, type of radioligand). Our experiments in mouse tissue and high-affinity transporter expressing cell lines help expand functional information of these transporters both in a commonly used model of preclinical relevance, and commonly used cell line. In experiments using D22 to displace binding of specific high-affinity radioligands for DAT, NET, and SERT in mouse brain tissue, we observed a ranking with D22 displacement efficiency in the order of DAT > SERT > NET (IC 50 values being~11 (DAT), 26 (SERT), and 101 (NET) µM; Figs. 1-3, Table 2 ). Although to a significantly lower extent than the high-affinity blocker cocaine, our data in heterologous, transiently expressed cells lines, show that D22, in contrast to corticosterone, can inhibit [ Table 3 ). However, given that 1) the affinity of psychotherapeutic drugs used clinically to target SERT, NET, and DAT (e.g. SSRIs, selective NET inhibitors) is in the nanomolar range (Frazer, 2001) , 2) plasma levels of these drugs in patients are typically in the 
IC 50 estimations determined from concentration response curves (Figs. 5 and 6) fit to a nonlinear regression. All values are shown as micromolar unless otherwise noted. a P < 0.05, aa P < 0.01, and aaa P < 0.001 indicates significance of difference, within each cell line, for the compound versus decynium 22. b P < 0.05, bb P < 0.01, and bbb P < 0.001 indicates significant differences for the compound versus hOCT3. cc P < 0.01 denotes significance compared to corticosterone, and ddd P < 0.001 denotes significance of comparison between hOCT2 and hPMAT.
ng/ml range (Boulton et al., 2010; Kaye et al., 1989) , and 3) doses of D22 required to produce behavioral effects in rodents are in the submilligram/kg range (Baganz et al., 2008; Horton et al., 2013) , it is highly unlikely that behaviorally relevant concentrations of D22 in extracellular fluid would reach the micromolar range required to block SERT, NET or DAT.
In general, most of the D22 analogs were more potent inhibitors of SERT and NET than D22. As depicted by dividing the IC 50 values for Concentrations of unlabeled competing D22 analogs ranged from 0 nM (control) up to 100 µM and are plotted on a log-scale. Uptake inhibition assays were performed at room temperature for 10 min. Data are fit to a non-linear regression analysis to determine IC 50 estimations (see Table 4 ). (Fig. 7 ), all 7 analogs had a potency ratio below 1 and thus favor binding to mSERT over mNET. Compounds 3 (P = 0.0019), 4, 6, and 7 (P < 0.0001) each have a markedly lower IC 50 value to inhibit SERT (mean IC 50 range 0.75-10 µM) than the parent D22, with the latter three compounds (4, 6, and 7, P < 0.0001) also being statistically more potent at SERT binding than the native substrate, serotonin (Table 2) . Compounds 4 (P < 0.001), 6 (P = 0.01), and 7 (P < 0.02) showed a significantly greater affinity to displace binding at DAT when compared to dopamine, as well. Based on having potency ratio values above 1 (Fig. 7) , parent D22, along with compounds 2 and 4 prefer binding at mDAT over binding to mSERT. All analogs either shared a similar or had a higher IC 50 value (thus, were less potent) than D22 to displace nisoxetine binding at NET.
Earlier work established D22 as a potent inhibitor of low-affinity/ high-capacity transporters, including OCT2, OCT3, and PMAT (Gasser et al., 2006 ; Hayer-Zillgen et al., 2002; Russ et al., 1992; Russ et al., 1993a Russ et al., , 1993b Russ et al., , 1996 Schomig et al., 1993; Shirasaka et al., 2016; Sun et al., 2014; Wang et al., 2014; Zhang et al., 1998) . In line with prior D22 action at hOCT3 (Hayer-Zillgen et al., 2002) , we found that D22 was a more potent inhibitor of [ 3 H]MPP + uptake at hOCT3 (IC 50 ≈ 0.2 µM) than hOCT2 (IC 50 ≈ 10 µM) and extended this finding to hPMAT (IC 50 ≈ 1 µM). The glucocorticoid corticosterone also inhibits OCT3-mediated transport and is extremely useful to probe OCT3 function. Our corticosterone competition data (Fig. 5C ) are similar to prior studies (Hayer-Zillgen et al., 2002) , where corticosterone preferentially bound to hOCT3 (IC 50 = 0.6 µM) relative to hOCT2 (IC 50 ≈ 80 µM). Corticosterone is also a poor blocker of hPMAT-driven transport (Engel et al., 2004; Russ et al., 1993a; Russ et al., 1993b) , as supported by its observed IC 50 ≈ 1 mM in our experiments, and in the literature (Engel et al., 2004; Miura et al., 2017) . The consistency of our results with the literature establishes an important platform on which to perform comparative analyses of D22 analogs in human transporter expressing cell lines. As seen in concentration-response analyses (Fig. 6 ) and summarized IC 50 data (Table 4) , all D22 analogs favored hOCT3 binding in comparison to hPMAT or hOCT2, apart from compound 2 where there was not a significant difference between the IC 50 values for hOCT2, hOCT3, or hPMAT. The inhibition potency at hOCT2 and hPMAT was equal for most analogs, except compound 3, which had a significantly higher IC 50 value, thus lower potency, to inhibit [ 3 H]MPP + uptake at hOCT2
(P = 0.0001 vs. hPMAT). Therefore, structural changes among many of the analogs do not appear to impart differences in binding affinities for hOCT2 or hPMAT. Taken together with data for D22 (IC 50 = 0.2 µM) and corticosterone (IC 50 = 0.6 µM), D22 analogs are potent hOCT3-prefering inhibitors with IC 50 values ranging from~0.4-2.6 µM ( Our overall goal is to develop selective compounds for low-affinity/ high-capacity transporters inhibitors (i.e. OCT1-3 and PMAT), and provide the field with much needed, specific pharmacological tools to study these transporters. In our initial efforts, we synthesized halogen substituted analogs and cyanine analogs of D22 yielding compounds that had greater affinity at hOCT3 rather than hOCT2 and hPMAT, however, none with improved selectivity for OCT3 over D22. Several compounds also had modest affinity for high-affinity/low-capacity monoamine transporters, SERT in particular, which may contribute to their "stand-alone" antidepressant-like effects we previously reported (Krause-Heuer et al., 2017) . For example, compound 6, which produced the most robust antidepressant-like effect (Krause-Heuer et al., 2017) , had the greatest affinity for SERT (0.75 µM), combined with affinity for OCT3 equivalent to corticosterone (0.77 µM). This contrasts to D22 with affinity values of 26.2 µM and 0.2 µM at SERT and OCT3, respectively. Thus, a possible reason for a lack of antidepressant-like effect of D22 on its own, in the absence of an SSRI (Horton et al., 2013) , is its relatively low affinity for SERT, thereby supporting our contention that combined SERT/OCT3 pharmacotherapeutics may have improved 3 H]nisoxetine binding at NET (closed squares) from mouse brain tissue preparations (as described earlier). For the unitless ratio obtained, values < 1 were more potent at mSERT and > 1 more potent at mDAT or mNET. An IC 50 ratio value of 1 indicates equipotency of the compound for both transporters of the comparison. A wider range of the y-axis is depicted to reflect the compounds with ratio values greater than 1.
efficacy for treating depression, and related serotonin-linked pathologies. The concept of targeting multiple transporters to achieve greater concentrations of extracellular monoamines is not new. However, tactics have largely focused on combined blockade of DAT, NET, SERT, monoamine receptors, and/or metabolism inhibitors (Moret, 2005; Sambunaris et al., 1997) . Current selective reuptake inhibitors for the high-affinity/low-capacity transporters (SERT, NET, DAT) have no appreciable activity at OCT2, OCT3, and PMAT (Emberger et al., 2011; Haenisch and Bönisch, 2010; Matthaeus et al., 2015; Wang et al., 2014; Zhou et al., 2007) . Work by us and others support the idea for greater therapeutic potential by blockade of the low-affinity/high-capacity transporter system, in tandem with blockers of high-affinity/low capacity transporters, especially in instances of resistance to high-affinity monoamine transporter therapies Hagan et al., 2011; Horton et al., 2013) . Our comparative analysis of this small library of D22 analogs identified select compounds that, unlike parent D22, lack activity at alpha-1 adrenoceptors, have independent antidepressant-like effects, and reduced potency to suppress spontaneous locomotion (Krause-Heuer et al., 2017) . The present study extends these findings to show that most analogs have significant binding preference for hOCT3 versus hOCT2 or hPMAT. Moreover, compounds 4, 6 and 7 show potential as drugs with selective action at the low-affinity transport system (OCT3), but also SERT and/or DAT binding ability.
Unlike D22, select D22 analogs were bimodal inhibitors of highaffinity transporters determined by their binding affinity at SERT and DAT. Since combination inhibitors can often be more efficacious than monotherapies (Moret, 2005) , this study supports the notion that the pharmacological method of dual blockade of both the low-affinity/ high-capacity and high-affinity/low-capacity transporter families can be of future value. Development of drugs with low-and high-affinity transporter blockade activity in a single compound warrants further investigation towards discovering improved treatments for disorders sub-optimally managed by currently available medications.
